Ignite Creation Date:
2025-12-24 @ 12:36 PM
Ignite Modification Date:
2026-01-20 @ 3:48 PM
Study NCT ID:
NCT00709761
Status:
COMPLETED
Last Update Posted:
2019-03-26
First Post:
2008-07-01
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Neoplasms, Breast | View |